Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis.

ALS ATXN2 C9orf72 ELAVL3 Loss of function Neurodegeneration Nuclear depletion RNA-binding proteins SOD1 TDP-43

Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
12 2021
Historique:
received: 27 05 2021
accepted: 21 09 2021
revised: 20 09 2021
pubmed: 8 10 2021
medline: 23 2 2022
entrez: 7 10 2021
Statut: ppublish

Résumé

Amyotrophic lateral sclerosis is a progressive fatal neurodegenerative disease caused by loss of motor neurons and characterized neuropathologically in almost all cases by nuclear depletion and cytoplasmic aggregation of TDP-43, a nuclear RNA-binding protein (RBP). We identified ELAVL3 as one of the most downregulated genes in our transcriptome profiles of laser captured microdissection of motor neurons from sporadic ALS nervous systems and the most dysregulated of all RBPs. Neuropathological characterizations showed ELAVL3 nuclear depletion in a great percentage of remnant motor neurons, sometimes accompanied by cytoplasmic accumulations. These abnormalities were common in sporadic cases with and without intermediate expansions in ATXN2 and familial cases carrying mutations in C9orf72 and SOD1. Depletion of ELAVL3 occurred at both the RNA and protein levels and a short protein isoform was identified, but it is not related to a TDP-43-dependent cryptic exon in intron 3. Strikingly, ELAVL3 abnormalities were more frequent than TDP-43 abnormalities and occurred in motor neurons still with normal nuclear TDP-43 present, but all neurons with abnormal TDP-43 also had abnormal ELAVL3. In a neuron-like cell culture model using SH-SY5Y cells, ELAVL3 mislocalization occurred weeks before TDP-43 abnormalities were seen. We interrogated genetic databases, but did not identify association of ELAVL3 genetic structure with ALS. Taken together, these findings suggest that ELAVL3 is an important RBP in ALS pathogenesis acquired early and the neuropathological data suggest that it is involved by loss of function rather than cytoplasmic toxicity.

Identifiants

pubmed: 34618203
doi: 10.1007/s00401-021-02374-4
pii: 10.1007/s00401-021-02374-4
pmc: PMC8568872
doi:

Substances chimiques

ELAV-Like Protein 3 0
ELAVL3 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

985-1001

Subventions

Organisme : NINDS NIH HHS
ID : P30 NS047101
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS088578
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS121805
Pays : United States
Organisme : NINDS NIH HHS
ID : R21NS121805
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Acta Neuropathol Commun. 2016 Sep 06;4(1):99
pubmed: 27600654
Biochim Biophys Acta Gene Regul Mech. 2018 Feb;1861(2):167-177
pubmed: 29413897
Nat Commun. 2019 May 1;10(1):2006
pubmed: 31043593
Virol J. 2014 Nov 20;11:192
pubmed: 25410318
Front Neurosci. 2019 Dec 06;13:1310
pubmed: 31866818
Nat Commun. 2019 Mar 1;10(1):990
pubmed: 30824702
Neurosci Res. 2018 Oct;135:13-20
pubmed: 29614249
Cell Mol Life Sci. 2008 Oct;65(20):3168-81
pubmed: 18581050
Nat Commun. 2016 Jul 05;7:12143
pubmed: 27378374
Hum Genet. 2017 Sep;136(9):1193-1214
pubmed: 28762175
Int J Mol Sci. 2014 Nov 06;15(11):20306-20
pubmed: 25383675
J Neurosci. 2011 Mar 9;31(10):3914-25
pubmed: 21389246
Curr Opin Neurol. 2019 Oct;32(5):735-739
pubmed: 31335339
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):20881-90
pubmed: 22065782
J Neurosci. 2010 Jan 13;30(2):639-49
pubmed: 20071528
J Autoimmun. 1999 Dec;13(4):435-43
pubmed: 10585760
Neurobiol Dis. 2013 Dec;60:51-60
pubmed: 23969235
Nat Neurosci. 2014 May;17(5):664-666
pubmed: 24686783
Nat Neurosci. 2019 Feb;22(2):180-190
pubmed: 30643298
Nucleic Acids Res. 2016 Jan 4;44(D1):D90-5
pubmed: 26602692
Sci Rep. 2018 Feb 9;8(1):2722
pubmed: 29426875
Nucleic Acids Res. 1997 Sep 15;25(18):3564-9
pubmed: 9278474
Cell Syst. 2021 Feb 17;12(2):159-175.e9
pubmed: 33382996
Trends Mol Med. 2014 Feb;20(2):66-71
pubmed: 24355761
Neuron. 2019 Apr 17;102(2):339-357.e7
pubmed: 30853299
Acta Neuropathol Commun. 2021 Feb 15;9(1):26
pubmed: 33588953
Sci Rep. 2017 Mar 16;7:44500
pubmed: 28300211
Int J Mol Sci. 2014 Feb 20;15(2):2946-58
pubmed: 24566137
Science. 2009 Feb 27;323(5918):1205-8
pubmed: 19251627
Acta Neuropathol. 2018 Sep;136(3):405-423
pubmed: 29881994
Hum Mol Genet. 2010 Jan 15;19(2):313-28
pubmed: 19864493
Neuron. 2018 Mar 21;97(6):1268-1283.e6
pubmed: 29566793
Orphanet J Rare Dis. 2009 Feb 03;4:3
pubmed: 19192301
J Neurosci. 1997 May 1;17(9):3024-37
pubmed: 9096138
RNA Biol. 2015;12(9):918-21
pubmed: 26158379
Ann Neurol. 1990 May;27(5):544-52
pubmed: 2163235
Neurobiol Dis. 2014 Nov;71:74-80
pubmed: 25088712
Neuron. 2012 Sep 20;75(6):1067-80
pubmed: 22998874
Hum Mol Genet. 2015 May 1;24(9):2565-77
pubmed: 25616961
Brain. 2011 Sep;134(Pt 9):2595-609
pubmed: 21856723
J Neurol. 2018 Jul;265(7):1590-1599
pubmed: 29725842
Neurology. 2007 May 8;68(19):1576-82
pubmed: 17485644
Brain. 2019 May 1;142(5):1176-1194
pubmed: 30938443
Acta Neuropathol Commun. 2019 Jan 14;7(1):7
pubmed: 30642400
Elife. 2016 Feb 19;5:
pubmed: 26894958
Lancet. 2011 Mar 12;377(9769):942-55
pubmed: 21296405
Nature. 2013 Mar 28;495(7442):467-73
pubmed: 23455423
Am J Med Genet B Neuropsychiatr Genet. 2011 Apr;156B(3):285-90
pubmed: 21438137
Nat Neurosci. 2019 Feb;22(2):167-179
pubmed: 30643292
Nature. 2016 Nov 10;539(7628):197-206
pubmed: 27830784
Neurodegener Dis. 2017;17(6):304-312
pubmed: 29131108
Sci Rep. 2017 Mar 14;7:44507
pubmed: 28291226
Cell Rep. 2019 Jun 25;27(13):3808-3817.e7
pubmed: 31242415
Ann Neurol. 2007 May;61(5):427-34
pubmed: 17469116
Mol Cells. 2018 Sep 30;41(9):818-829
pubmed: 30157547
Biochim Biophys Acta. 2015 Dec;1849(12):1398-410
pubmed: 26514432
Cell Rep. 2019 Jun 25;27(13):3818-3831.e5
pubmed: 31242416

Auteurs

Sandra Diaz-Garcia (S)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, 92093-0670, USA.

Vivian I Ko (VI)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, 92093-0670, USA.

Sonia Vazquez-Sanchez (S)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, 92093-0670, USA.
Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.

Ruth Chia (R)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892-3707, USA.

Olubankole Aladesuyi Arogundade (OA)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, 92093-0670, USA.

Maria J Rodriguez (MJ)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, 92093-0670, USA.

Bryan J Traynor (BJ)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892-3707, USA.

Don Cleveland (D)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, 92093-0670, USA.
Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.

John Ravits (J)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, 92093-0670, USA. jravits@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH